Last updated: May 28, 2026
Prasugrel supply is driven by a limited set of global API and dosage-form manufacturers. The commercial supply chain is typically split between (1) active pharmaceutical ingredient (API) producers, (2) finished-dose drug product manufacturers, and (3) packaging and secondary supply-chain partners listed on regulatory filings and product labeling. Across jurisdictions, the same handful of API and contract manufacturing organizations repeat on product dossiers and marketing-authorisation records for prasugrel-containing tablets.
Which companies supply prasugrel API (active pharmaceutical ingredient)?
Answer: Prasugrel API sourcing is concentrated among a small number of CMO and API specialists that also support process scale-up, polymorph control, impurity profiling, and validation for solid oral tablets.
What APIs exist for prasugrel tablets?
- The active ingredient is prasugrel hydrochloride (typically described in dossiers as prasugrel or prasugrel hydrochloride, depending on regulatory convention).
- API suppliers usually provide:
- prasugrel hydrochloride drug substance
- compliance documentation (GMP status, impurity specification, CoA release)
- stability packages supporting shelf-life for tablets
How do API suppliers map to finished-dose supply?
In practice, finished-dose manufacturers do not always list API suppliers on the label, but the same supplier set appears in:
- regulatory chemistry, manufacturing, and controls (CMC) sections
- EU marketing-authorisation product information and assessment reports
- FDA manufacturing site listings (when provided in submissions or in publicly indexed databases)
Which companies supply prasugrel finished tablets (dosage form) in the US?
Answer: Finished-dose manufacturing is concentrated among the original brand manufacturer’s commercial supply chain and a set of contract manufacturing organizations that produce and package solid oral tablets at scale.
What dosage forms are supplied?
- Prasugrel tablets (oral solid dosage form)
- Strengths vary by market listing and original marketing authorization
How do finished-dose suppliers get listed for prasugrel?
Finished-dose suppliers are tied to:
- the NDA/BLA product site(s) named in regulatory filings and inspection history
- contract manufacturing steps (tablet compression, coating, blistering, bottling)
- packaging operations (labeling, secondary packaging, serialization where required)
Who manufactures prasugrel tablets for generic and authorized-competition products?
Answer: Generic and authorized-competition supply uses:
- API from a narrow set of global API producers
- drug product manufacturing by companies that are active across multiple solid oral portfolios
- packaging and distribution partners that support country-specific logistics
What patent or exclusivity constraints matter for supply?
Supply timing for generics depends on:
- the brand’s exclusivity window (5-year new chemical entity or other relevant exclusivity, where applicable)
- any patent estates that block non-infringing product entry
- Paragraph IV litigation outcomes when challenges are filed
(These constraints affect market entrants, not the existence of API capability, since API capability is usually broader than final product approval.)
What packaging and distribution suppliers support prasugrel tablets?
Answer: Secondary packaging suppliers and distribution nodes are typically less visible to end users than API and tablet manufacturing sites, but they recur in regulatory dossiers and inspection records through:
- blister packaging and bottling operations
- quality systems for inbound/outbound chain of custody
- cold-chain is generally not required for standard prasugrel tablets (solid oral)
How to identify prasugrel suppliers from regulatory sources?
Answer: The supplier list is built by triangulating:
- FDA labeling and manufacturing site data for marketed product configurations
- EU product dossier and manufacturing authorisation records (where accessible)
- inspection and establishment lists that match manufacturing categories (API, finished dose, packaging)
What specific records typically expose supplier names?
- Drug product establishment listings associated with marketing authorizations
- Site information used in CMC modules for manufacturing and control
- GMP inspection coverage that ties an establishment to a product family
What procurement risks exist when selecting prasugrel suppliers?
Answer: Key procurement risks for prasugrel supply chains are concentration risk (few API sources), process-change control, and impurity specification sensitivity.
Common operational risks
- API batch-to-batch control: impurity profile drift can force re-testing or re-release
- Process validation burden: contract manufacturers require strict change control
- Raw-material volatility: precursor availability can create lead-time surges
- Regulatory inspection outcomes: one site’s findings can reduce allocatable supply
Key Takeaways
- Prasugrel supply is concentrated across a small number of global API and finished-dose manufacturers.
- API and dosage-form manufacturing are commonly handled by specialized CMO/API suppliers supporting solid oral tablet programs.
- Supplier identification for procurement is best done by mapping regulatory establishment records to the branded and generic marketing authorizations for prasugrel tablets.
- The main commercial risk for prasugrel is supplier concentration and impurity/process sensitivity that affects release schedules.
FAQs
1) What is the active ingredient in prasugrel tablets?
Prasugrel hydrochloride is the active ingredient used in prasugrel tablet products.
2) Do prasugrel labels usually name the API supplier?
Most labels do not name the API supplier; API sourcing is usually visible in regulatory CMC content and establishment listings rather than on consumer-facing packaging.
3) Are prasugrel tablets blister-packed or bottle-packed?
Both packaging formats are used depending on market, product configuration, and distribution requirements.
4) What manufacturing types are most relevant for prasugrel supply?
Drug substance (API) manufacturing, finished-dose tablet manufacturing (compression/coating), and packaging/labeling operations.
5) Why can prasugrel supply be harder to scale quickly than some other solid oral drugs?
Supplier concentration and tight impurity and process validation requirements for API releases can slow scale-up and extend lead times.
References
- FDA. Drugs@FDA. US product and application information for prasugrel (search portal).
- EMA. European Medicines Agency. EPAR and related documents for prasugrel-containing products (market authorization records).
- FDA. Orange Book. Patent and exclusivity listings tied to prasugrel product entry status (portal).
